Suppr超能文献

长期随访期间胺碘酮与华法林相互作用的特征。

Characteristics of the amiodarone-warfarin interaction during long-term follow-up.

作者信息

Lu Yun, Won Katie A, Nelson Brenda J, Qi Dongfeng, Rausch Douglas J, Asinger Richard W

机构信息

Department of Pharmacy, Hennepin County Medical Center (HCMC), Minneapolis, MN 55415, USA.

出版信息

Am J Health Syst Pharm. 2008 May 15;65(10):947-52. doi: 10.2146/ajhp060415.

Abstract

PURPOSE

Characteristics of the amiodarone-warfarin interaction during long-term follow-up were studied.

METHODS

Medical records from patients seen in the anticoagulation clinic at the Hennepin County Medical Center between April 1998 and March 2003 were retrospectively reviewed. Patients were included if they were older than 18 years, used the anticoagulation clinic as their primary clinic for anticoagulation therapy, and were receiving combined amiodarone and warfarin therapy for at least one month. The primary study endpoint was the occurrence of International Normalized Ratios (INRs) of >5 at any time during combined warfarin-amiodarone therapy. The secondary endpoint was the frequency of warfarin dosage changes.

RESULTS

A total of 70 patients met study inclusion criteria. Of these 70, 7 had amiodarone started before warfarin initiation. Of the 2434 INR values analyzed, 43% (n = 1043) were in the target therapeutic range, 34% (n = 820) were below target range, and 23% (n = 571) were above target range. A total of 102 INR values (4%) were above 5. The relative risk of having an INR of >5 for patients on concurrent warfarin and amiodarone versus those on warfarin alone was 1.366 (p = 0.005). INRs of >5 were most common during the first 12 weeks of combined therapy, with no subsequent large peaks evident.

CONCLUSION

Among patients treated in an anticoagulation clinic, INR values of >5 were most common during the first 12 weeks of combined therapy with amiodarone and warfarin and necessitated reduction in warfarin dosage. No other notable changes in INR or amiodarone or warfarin dosage occurred throughout the remainder of the 80-week study period.

摘要

目的

研究长期随访期间胺碘酮与华法林相互作用的特征。

方法

回顾性分析1998年4月至2003年3月在亨内平县医疗中心抗凝门诊就诊患者的病历。纳入年龄大于18岁、以抗凝门诊作为主要抗凝治疗门诊且接受胺碘酮和华法林联合治疗至少1个月的患者。主要研究终点是在华法林 - 胺碘酮联合治疗期间任何时间国际标准化比值(INR)>5的发生情况。次要终点是华法林剂量变化的频率。

结果

共有70例患者符合研究纳入标准。其中7例在华法林起始前开始使用胺碘酮。在分析的2434个INR值中,43%(n = 1043)处于目标治疗范围,34%(n = 820)低于目标范围,23%(n = 571)高于目标范围。共有102个INR值(4%)高于5。同时使用华法林和胺碘酮的患者INR>5的相对风险与仅使用华法林的患者相比为1.366(p = 0.005)。INR>5在联合治疗的前12周最为常见,随后无明显大的峰值出现。

结论

在抗凝门诊接受治疗的患者中,胺碘酮与华法林联合治疗的前12周INR值>5最为常见,需要减少华法林剂量。在为期80周的研究期的其余时间里,INR、胺碘酮或华法林剂量没有其他显著变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验